| Drug ID: | Drug85 |
|---|---|
| Drug Name: | Butyrate |
| CID: | 5222465 |
| DrugBank ID: | NULL |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NCT05218850 |
| Molecular Formula: | C4H7NaO2 |
| Molecular Weight: | 110.09 g/mol |
| Isomeric SMILES: | CCCC(=O)[O-].[Na+] |
| Synonyms: | SODIUM BUTYRATE; 156-54-7; Butyric acid sodium salt; Butanoic acid, sodium salt; Butyrate sodium; Butyric acid, sodium salt; CCRIS 7068; Sodium butyrate (USP); Sodium butyrate [USP]; HSDB 5655 |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt706 | 5222465 | Sodium Butyrate | 3689 | ITGB2 | Homo sapiens (human) | None | |
| dt707 | 5222465 | Sodium Butyrate | 2026 | ENO2 | Homo sapiens (human) | None | |
| dt708 | 5222465 | Sodium Butyrate | 2670 | GFAP | Homo sapiens (human) | None | |
| dt709 | 5222465 | Sodium Butyrate | 2641 | GCG | Homo sapiens (human) | None | |
| dt710 | 5222465 | Sodium Butyrate | 7052 | TGM2 | Homo sapiens (human) | None | |
| dt711 | 5222465 | Sodium Butyrate | 3065 | HDAC1 | Homo sapiens (human) | Inhibitor | |
| dt712 | 5222465 | Sodium Butyrate | 64061 | TSPYL2 | Homo sapiens (human) | None | |
| dt713 | 5222465 | Sodium Butyrate | 4363 | ABCC1 | Homo sapiens (human) | None | |
| dt714 | 5222465 | Sodium Butyrate | 6696 | SPP1 | Homo sapiens (human) | None | |
| dt715 | 5222465 | Sodium Butyrate | 94025 | MUC16 | Homo sapiens (human) | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06351124 | Feasibility of Beta-hydroxybutyrate Supplementation to Reduce Inflammation in Patients with Inflammatory Bowel Disease | PHASE1|PHASE2 | Recruiting | University of Texas at Austin | Crohn's Disease;Inflammatory Bowel Diseases | Biological: Feasibility of beta-hydroxybutyrate s… | Details |
| NCT04879914 | Inflammation and Intestinal Microbiota Modulation in Inflammatory Bowel Diseases | Not Available | Not recruiting | University of Padova | Inflammatory Bowel Diseases;Irritable Bowel Syndr… | Dietary Supplement: Butyrate;Dietary Supplement: … | Details |
| NCT05456763 | Butyrate in Pediatric Inflammatory Bowel Disease | None | COMPLETED | Centre of Postgraduate Medical Education | Inflammatory Bowel Diseases | DIETARY_SUPPLEMENT: sodium butyrate|OTHER: placebo | Details |
| NCT05218850 | The Use of Butyrate Therapy in Pediatric Ulcerative Colitis | PHASE1 | RECRUITING | Children's Hospital Los Angeles | Ulcerative Colitis | DRUG: Butyrate | Details |
| NCT04259060 | Hydroxocobalamin Approach for Reducing of Calprotectin With Butyrate for Ulcerative Colitis Remission | PHASE2 | WITHDRAWN | Joshua Korzenik | Ulcerative Colitis | DRUG: Hydroxocobalamin with Butyrate|DRUG: Placeb… | Details |
| NCT01282905 | Hydrogen Sulfide Detoxification and Butyrate Metabolism in Ulcerative Colitis | None | COMPLETED | KU Leuven | Ulcerative Colitis | None | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Heat-shock transcription factor 2 promotes sodium butyrate-induced autophagy by…
PMID: 31923427
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Butyrate-induced autophagy and anti-inflammatory effects of IECs plays an important role in UC. HSP has been proved to be associated with autophagy. …
Deletion of the Casp8 gene in mice results in ileocolitis, gut barrier dysfunct…
PMID: 31411503
Year: 2019
Relationship Type:
Treatment
Score: 6.5
Genetically modified mice have been successfully used as models for inflammatory bowel diseases; however, dietary effects were poorly examined. Here,…
Oral administration of sodium butyrate attenuates inflammation and mucosal lesi…
PMID: 21658926
Year: 2012
Relationship Type:
Treatment
Score: 6.1
Butyrate is a four-carbon short-chain fatty acid that improves colonic trophism. Although several studies have shown the benefits of butyrate enemas …
Butyrate Inhibits the HDAC8/NF-κB Pathway to Enhance Slc26a3 Expression and Imp…
PMID: 39440960
Year: 2024
Relationship Type:
Mechanism
Score: 5.5
Dietary fiber is known to promote the production of short-chain fatty acids (SCFAs) by gut bacteria, which can enhance intestinal epithelial barrier …
Applications and Mechanism of 3-Hydroxybutyrate (3HB) for Prevention of Colonic…
PMID: 34704372
Year: 2021
Relationship Type:
Mechanism
Score: 5.5
SCOPE: Inflammatory bowel disease and colorectal carcinogenesis (CRC) are common diseases without effective prevention approach. 3-Hydroxybutyrate (3…
Sodium butyrate inhibits the NF-kappa B signaling pathway and histone deacetyla…
PMID: 28802151
Year: 2017
Relationship Type:
Treatment
Score: 5.3
Butyrate is a bacterial metabolite of dietary fiber in the colon that has been used to treat inflammatory disease. However, the effect of oral supple…